Loading companies…
Loading companies…
United States · Biotech · AI
Develops a novel class of potent and precise antibody therapies to treat a broad range of cancers
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $77M | Arkin Bio Capital — Role not disclosedBlood Cancer United's Therapy Acceleration Program — Role not disclosedBVF Partners — Role not disclosedEli Lilly and Company — Role not disclosedHamilton Square Partners — Role not disclosedLibbs Ventures — Role not disclosedLifeLink Ventures — Role not disclosedMirae Asset Venture Investment — Role not disclosedMPM BioImpact — Role not disclosedPfizer Ventures — Role not disclosedPolaris Partners — Role not disclosedSixty Degree Capital — Role not disclosedTaiho Ventures — Role not disclosed |